A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Tetsuji TakabayashiDaiya AsakaYoshitaka OkamotoTetsuo HimiShinichi HarunaNaohiro YoshidaKenji KondoMamoru YoshikawaYasunori SakumaKunihiko ShibataMotohiko SuzukiMasayoshi KobayashiRyo KawataKenzo TsuzukiMitsuhiro OkanoTakaya HigakiSachio TakenoSatoru KodamaSyuji YonekuraHiromi SaitoAkiyo NozakiNobuyoshi OtoriShigeharu FujiedaPublished in: American journal of rhinology & allergy (2021)
Although benralizumab did not meet the primary efficacy endpoint, reductions of nasal polyp scores were seen in the benralizumab group compared with the placebo group over the whole study period, especially in patients with high levels of blood eosinophils.